News Three more biotechs price their Nasdaq IPOs AgomAb, SpyGlass, and Veradermics have all set the terms for their IPOs this week, looking to raise somewhere between around $150m and $200m.
News AgomAb and SpyGlass push the IPO button Glimmers of a renewal of biotech IPO activity in 2026 have continued with the news that AgomAb and SpyGlass Pharma are sizing up investor interest.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
